Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% |
|
0.00% | 0.00% |
08/05 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
05/03 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Business Summary
Number of employees: 4
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Clinical-stage Life Sciences
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 01/17/01 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 13/20/13 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Corporate Secretary | - | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22/20/22 | |
Thian Chew
CEO | Chief Executive Officer | - | 01/17/01 |
Alan Yamashita
BRD | Director/Board Member | 74 | 12/19/12 |
Rob Merriel
BRD | Director/Board Member | - | 31/20/31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,421,632,206 | 3,278,698,334 ( 51.06 %) | 0 | 51.06 % |
Company contact information
![address Invion Limited(IVX)](https://cdn.zonebourse.com/static/address/11401230.png)
Sector
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.13Cr | |
+34.14% | 5.11TCr | |
-6.54% | 3.94TCr | |
+34.92% | 3.85TCr | |
+12.62% | 2.64TCr | |
-12.11% | 2.62TCr | |
-13.43% | 2.1TCr | |
+43.73% | 1.4TCr | |
+31.81% | 1.25TCr | |
-4.54% | 1.16TCr |
- Stock Market
- Equities
- IVX Stock
- Company Invion Limited